Abstract
Objective: The purpose of this study was to review the efficacy and cost-effectiveness of Glucosamine.
Method: A review of meta-analysis, randomized controlled trial with at least 12-month follow-up
in patients and cost-effectiveness analysis of Glucosamine between 2005-2010 was undertaken. The review
did not consider old studies because there was evidence suggesting publication bias.
Results: Compared with placebo Glucosamine was no more effective than placebo (statistical nondifference)
in people with osteoarthritis on WOMAC pain and WOMAC function, RMDQ and EQ-5D
scores also showed no or small effect on narrowing the joint space width. Both generic and innovative
Glucosamine had ICER greater than one time Thai GDP per capita.
Conclusion: Available evidence suggests that Glucosamine has low effect, therefore low cost-effectiveness.
Up until now it is still a controversial issue among prescribers and health insurers, especially the
in the Civil Servant Medical Benefit Scheme that whether it should be included the cost of treatment in
public health insurance system.
